Irreversible opiate agonists and antagonists: the 14- hydroxydihydromorphinone azines

Further investigations into the molecular actions of the 14- hydroxydihydromorphinone hydrazones (naloxazone, oxymorphazone, and naltrexazone) have suggested that their irreversible actions can be explained by the formation of their azines. These azines, naloxonazine, naltrexonazine, and oxymorphonazine, irreversibly block opiate binding in vitro 20- to 40-fold more potently than their corresponding hydrozones, naloxazone, naltrexazone, and oxymorphazone. The blockade of binding by naloxonazine shows the same selectivity for high affinity, or mu1, sites as naloxazone.

[1]  G. Pasternak.  Opiate, enkephalin, and endorphin analgesia , 1981, Neurology.

[2]  G. Pasternak,et al.  The binding and analgesic properties of a sigma opiate, SKF 10,047. , 1981, The Journal of pharmacology and experimental therapeutics.

[3]  G. Pasternak,et al.  Classification of multiple morphine and enkephalin binding sites in the central nervous system. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Pasternak,et al.  Opiates and enkephalins: a common binding site mediates their analgesic actions in rats. , 1981, Life sciences.

[5]  S. Snyder,et al.  Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. , 1981, Science.

[6]  G. Pasternak,et al.  Naloxazone irreversibly inhibits the high affinity binding of [125I]D-ala2-D-leu5-enkephalin. , 1981, Life sciences.

[7]  S. Snyder,et al.  Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro. , 1980, The Journal of pharmacology and experimental therapeutics.

[8]  G. Pasternak.  Multiple opiate receptors: [3H]ethylketocyclazocine receptor binding and ketocyclazocine analgesia. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Pasternak,et al.  Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones. , 1980, Journal of medicinal chemistry.

[10]  G. Pasternak,et al.  Opiate Analgesia: Evidence for Mediation by a Subpopulation of Opiate Receptors , 1980 .

[11]  D. L. Larson,et al.  A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. , 1980, Journal of medicinal chemistry.

[12]  D. L. Larson,et al.  Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity. , 1979, Science.

[13]  D. L. Larson,et al.  Synthesis and pharmacologic characterization of an alkylating analogue (chlornaltrexamine) of naltrexone with ultralong-lasting narcotic antagonist properties. , 1979, Journal of medicinal chemistry.

[14]  D. L. Larson,et al.  6β-(N,N-BIS(2-CHLOROETHYL)AMINO)-17-(CYCLOPROPYLMETHYL)-4,5α-EPOXY-3# ,14-DIHYDROXYMORPHINAN (CHLORANALTREXAMINE), A POTENT OPIOID RECEPTOR ALKYLATING AGENT WITH ULTRALONG NARCOTIC ANTAGONIST ACTIVITY , 1978 .

[15]  R. Schulz,et al.  Irreversible alteration of opiate receptor function by a photoaffinity labelling reagent. , 1975, Life sciences.

[16]  S. Snyder,et al.  Differential effects of protein-modifying reagents on receptor binding of opiate agonists and antagonists. , 1975, Molecular pharmacology.

[17]  A. Goldstein,et al.  A photochemical affinity-labelling reagent for the opiate receptor(s). , 1972, Molecular pharmacology.

[18]  J. Changeux,et al.  Use of a snake venom toxin to characterize the cholinergic receptor protein. , 1970, Proceedings of the National Academy of Sciences of the United States of America.